SequelSEC

Kura Oncology, Inc. KURA

Pharmaceutical Preparations · CIK 0001422143 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$20.87M
Fiscal year ended 2026-06-30
Operating income
-$73.01M
Fiscal year ended 2026-06-30
Free cash flow
-$63.20M
Fiscal year ended 2026-06-30

Kura Oncology, Inc. (KURA) reported revenue of $20.87M and net income of -$68.33M for the fiscal year ended 2026-06-30. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from Kura Oncology, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Kura Oncology, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312023-12-31
Revenue$20.87M$18.26M$17.34M$20.75M$15.29M$14.11MUnavailableUnavailable
Cost of revenue$243.00K$262.00KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profit$20.63M$18.00MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$73.01M-$78.82M-$86.27M-$80.00M-$72.67M-$64.70MUnavailableUnavailable
Net income-$68.33M-$73.33M-$81.00M-$74.12M-$66.12M-$57.43MUnavailableUnavailable
Research & development$61.89M$65.26M$64.41M$67.91M$62.78M$55.97MUnavailableUnavailable
Weighted-average diluted sharesshares 88.86Mshares 88.61MUnavailableshares 87.64Mshares 87.59Mshares 87.42MUnavailableUnavailable
Pretax income-$68.32M-$73.32M-$80.93M-$74.12M-$66.12M-$57.20MUnavailableUnavailable
Income tax expense$5.00K$8.00K$71.00K$0$0$226.00KUnavailableUnavailable
Diluted EPS$-0.77$-0.83Unavailable$-0.85$-0.75$-0.66UnavailableUnavailable
Selling, general & administrative$31.75M$31.56MUnavailableUnavailable$25.17M$22.84MUnavailableUnavailable
General & administrativeUnavailableUnavailableUnavailable$32.84M$25.17M$22.84MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Kura Oncology, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312023-12-31
Cash & equivalents$70.24M$39.08M$149.10M$95.29M$81.95M$51.27M$224.46M$37.32M
Total assets$587.79M$652.55M$738.36M$649.38M$682.42M$743.76M$760.16M$448.94M
Current assets$559.44M$623.78M$708.66M$620.66M$660.08M$724.20M$744.83M$432.48M
Total liabilities$539.36M$544.67M$564.23M$406.84M$376.94M$379.36M$346.52M$51.66M
Current liabilities$118.19M$101.50M$116.97M$121.30M$107.17M$89.77M$78.71M$35.26M
Total equity incl. NCI$48.43M$107.88M$174.14M$242.54M$305.49M$364.41M$413.64M$397.27M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$2.48M$843.00K$413.00KUnavailableUnavailableUnavailable$0Unavailable
Accounts receivable$9.45M$9.35M$8.80M$35.94M$4.57M$48.75M$2.06MUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$5.57M$9.75M$9.71M$5.34M$6.51M$7.65M$6.92M$9.33M
Accounts payable$2.39M$7.04M$5.02M$4.67M$1.70M$4.61M$1.47M$2.30M

Cash flow

Kura Oncology, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312023-12-31
Operating cash flow-$62.55M-$85.85M$117.27M-$80.63M-$28.78M-$71.93MUnavailableUnavailable
Capital expenditures$656.00K$128.00K$2.32M$2.57M$1.46M$292.00KUnavailableUnavailable
Investing cash flow$92.21M-$24.23M-$64.60M$93.97M$58.94M-$101.41MUnavailableUnavailable
Financing cash flow$1.50M$69.00K$1.14M$0$515.00K$143.00KUnavailableUnavailable
Net change in cash$31.16M-$110.02M$53.81M$13.34M$30.68M-$173.19MUnavailableUnavailable
Stock-based compensation$8.21M$8.42M$11.35M$10.96M$6.95M$7.84MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Kura Oncology, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312023-12-31
Free cash flow-$63.20M-$85.98M$114.95M-$83.19M-$30.24M-$72.22MUnavailableUnavailable
Gross margin98.8%98.6%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-349.8%-431.5%-497.6%-385.5%-475.3%-458.6%UnavailableUnavailable
FCF margin-302.8%-470.7%663.1%-400.9%-197.8%-511.9%UnavailableUnavailable
SBC / revenue39.3%46.1%65.5%52.8%45.5%55.6%UnavailableUnavailable
Current ratio4.73x6.15x6.06x5.12x6.16x8.07x9.46x12.26x
Revenue YoY growth36.5%29.5%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net margin-327.3%Unavailable-467.2%-357.2%-432.5%UnavailableUnavailableUnavailable
R&D / revenue296.5%357.3%371.5%327.3%410.7%396.7%UnavailableUnavailable
CapEx / revenue3.1%0.7%13.4%12.4%9.5%2.1%UnavailableUnavailable
Long-term debt / equity0.12xUnavailable0.06x0.02xUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open KURA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.